title: Early intervention with intranasal NPY prevents single prolonged stress-triggered impairments in hypothalamus and ventral hippocampus in male rats.
abstract: Intranasal administration of neuropeptide Y (NPY) is a promising treatment strategy to reduce traumatic stress-induced neuropsychiatric symptoms of posttraumatic stress disorder (PTSD). We evaluated the potential of intranasal NPY to prevent dysfunction of the hypothalamic-pituitary-adrenal (HPA) axis, a core neuroendocrine feature of PTSD. Rats were exposed to single prolonged stress (SPS), a PTSD animal model, and infused intranasally with vehicle or NPY immediately after SPS stressors. After 7 days undisturbed, hypothalamus and hippocampus, 2 structures regulating the HPA axis activity, were examined for changes in glucocorticoid receptor (GR) and CRH expression. Plasma ACTH and corticosterone, and hypothalamic CRH mRNA, were significantly higher in the vehicle but not NPY-treated group, compared with unstressed controls. Although total GR levels were not altered in hypothalamus, a significant decrease of GR phosphorylated on Ser232 and increased FK506-binding protein 5 mRNA were observed with the vehicle but not in animals infused with intranasal NPY. In contrast, in the ventral hippocampus, only vehicle-treated animals demonstrated elevated GR protein expression and increased GR phosphorylation on Ser232, specifically in the nuclear fraction. Additionally, SPS-induced increase of CRH mRNA in the ventral hippocampus was accompanied by apparent decrease of CRH peptide particularly in the CA3 subfield, both prevented by NPY. The results show that early intervention with intranasal NPY can prevent traumatic stress-triggered dysregulation of the HPA axis likely by restoring HPA axis proper negative feedback inhibition via GR. Thus, intranasal NPY has a potential as a noninvasive therapy to prevent negative effects of traumatic stress.
authors: Department of Biochemistry and Molecular Biology (M.L., L.G.A., L.I.S., E.L.S.), New York Medical College, Valhalla, New York 10595; and Molecular Imaging and Neuropathology Division (V.A.), New York State Psychiatric Institute, New York, New York 10032.
authors: Marcela
authors: M
authors: Laukova
authors: Lishay G
authors: LG
authors: Alaluf
authors: Lidia I
authors: LI
authors: Serova
authors: Victoria
authors: V
authors: Arango
authors: Esther L
authors: EL
authors: Sabban
mesh_terms: D000281:Administration, Intranasal; D000818:Animals; D006624:Hippocampus / Q000187:drug effects* / Q000503:physiopathology; D007027:Hypothalamic Diseases / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects / Q000503:physiopathology; D007031:Hypothalamus / Q000187:drug effects / Q000503:physiopathology; D008297:Male; D009478:Neuropeptide Y / Q000008:administration & dosage*; D010913:Pituitary-Adrenal System / Q000187:drug effects / Q000503:physiopathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013313:Stress Disorders, Post-Traumatic / Q000150:complications* / Q000188:drug therapy* / Q000523:psychology; D013315:Stress, Psychological / Q000150:complications / Q000188:drug therapy*
chemical_list: D009478:Neuropeptide Y